Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Order Online! Now! Get your $50 coupon for online order. 
Get 50% off discount for CGT related product lines!
Our limited edition HOLIDAYS LLAMA is here! Place any order now to recieve one! Earn Loyalty Rewards! Up to $155 Amazon Gift Card
Time Limited Offer: Welcome Gift for New Customers ! Time Limited Offer: Welcome Gift for New Customers !
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CDE-BV84G0 | Mouse | Biotinylated Anti-Human CD3 Antibody, Mouse IgG2a,Avitag™ (Clone: OKT3), premium grade |
|
|
|
| CDE-M532 | Mouse | Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (UCHT1) |
|
|
|
| CDE-M531 | Mouse | Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (SP34-2) |
|
|
|
| CHEK-ACD080 | Human | HEK293/Human CD3E & CD3D & CD3G & CD3Z Stable Cell Line | |||
| GMP-MC0323 | Mouse | GMP Monoclonal Anti-Human CD3 Antibody (OKT3) |
|
||
| CDE-M120a | Mouse | Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), premium grade |
|
5e5 of Jurkat cells were stained with 100 μL of 0.3 μg/mL of Biotinylated Anti-Human CD3 Antibody, Mouse IgG2a,Avitag (Clone: OKT3), premium grade (Cat. No. CDE-BV84G0) and isotype control antibody respectively, washed and then followed by PE-SA and analyzed with FACS (Routinely tested).
2e5 of Jurkat cells were stained with 100 μL of 1 μg/mL of Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (UCHT1) (Cat. No. CDE-M532) and isotype control antibody respectively, washed and then followed by PE-anti mouse IgG1 antibody and analyzed with FACS (Routinely tested).
Immobilized Human CD3E&CD3D Heterodimer Protein (Cat. No. CDD-H52Wa) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD3 Antibody, Mouse IgG1 (UCHT1) (Cat. No. CDE-M532) with a linear range of 0.1-3 ng/mL (QC tested).
The purity of Biotinylated Anti-Human CD3 Antibody, Mouse IgG2a,Avitag (Clone: OKT3), premium grade (Cat. No. CDE-BV84G0) is more than 95% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Janssen Global Services Llc | TECAYLI | EU | Multiple Myeloma | Janssen Biotech Inc | 2022-08-23 | Hematologic Diseases; Hematologic Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Tebentafusp | IMC-gp-100; IMC-gp100; ImmTAC-gp-100 | Approved | Immunocore Ltd | KIMMTRAK | United States | Uveal melanoma | Medison Pharma | 2022-01-25 | Uveal melanoma; Melanoma | Details |
| Mouse monoclonal antibody against human CD3 antigen of T lymphocyte (Wuhan Institute of Biological Products) | Approved | Wuhan Institute Of Biological Products Co Ltd | Mainland China | Rejection of organ transplantation | Wuhan Institute Of Biological Products Co Ltd | 1999-01-01 | Rejection of organ transplantation | Details | ||
| Blinatumomab | MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 | Approved | Amgen Inc | Blincyto, 倍利妥 | United States | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Lymphoma, B-Cell; Leukemia; Neoplasm, Residual; Leukemia, Myelogenous, Chronic; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Mosunetuzumab | BTCT-4465A; RO-7030816; RG-7828 | Approved | Genentech Inc | Lunsumio | EU | Lymphoma, Follicular | Roche Registration Gmbh | 2022-06-03 | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Teplizumab | PRV-031; MGA-031; hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala | Approved | Macrogenics Inc | TZIELD | United States | Diabetes Mellitus, Type 1 | Provention Bio Inc | 2022-11-17 | Diabetes Mellitus, Type 1; Rejection of renal transplantation; Glucose Intolerance; Hypoglycemia; Psoriasis; Diabetes Mellitus, Experimental | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Vibecotamab | XmAb-14045 | Phase 1 Clinical | Xencor Inc | Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus Nv | Psoriasis; Lymphoma, T-Cell | Details |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | Multiple Myeloma | Details |
| QLS-31905 | QLS-31905 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
| BS-006 | BS-006 | Phase 1 Clinical | Solid tumours; Melanoma; Uterine Cervical Neoplasms | Details | |
| CCW-702 | CCW-702 | Phase 1 Clinical | The Scripps Research Institute Inc, Abbvie Inc | Prostatic Neoplasms | Details |
| RG-6007 | RG-6007 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Leukemia, Myeloid, Acute | Details |
| JNJ-80948543 | JNJ-80948543 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Solid tumours; Chondrosarcoma; Leukemia; Neoplasms; Hodgkin Disease; Neuroblastoma; Lymphoma | Details | |
| GEN-1047 | GEN-1047 | Phase 2 Clinical | Genmab A/S | Ovarian Neoplasms; Breast Neoplasms; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Plamotamab | XmAb-13676 | Phase 2 Clinical | Xencor Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Pancreatic Neoplasms | Details | |
| RG-6234 | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
| JNJ-63898081 | JNJ-8081; JNJ-63898081 | Phase 1 Clinical | Janssen Global Services Llc | Neoplasms | Details |
| WVT-078(Novartis Pharma) | WVT-078 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| IBI-389 | IBI-389 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
| Imvotamab | IGM-2323 | Phase 2 Clinical | Igm Biosciences Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Azintuxizumab | TNB-383B; ABBV-383 | Phase 2 Clinical | Teneobio Inc, Abbvie Inc | Multiple Myeloma | Details |
| XmAb-819 | XmAb-819 | Phase 1 Clinical | Xencor Inc | Kidney Neoplasms; Carcinoma, Renal Cell | Details |
| Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| BC-3448 | BC-3448; BC3448 | Phase 1 Clinical | Wuxi Zhikang Hongyi Biological Technology Co Ltd | Solid tumours | Details |
| EMB-06 | EMB-06; EMB06 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Multiple Myeloma | Details |
| PF-07062119 | PF-07062119 | Phase 1 Clinical | Pfizer Pharmaceuticals Ltd (China) | Stomach Neoplasms; Large intestine neoplasm; Adenocarcinoma; Gastrointestinal Neoplasms | Details |
| A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
| HPN-536 | HPN-536 | Phase 2 Clinical | Harpoon Therapeutics | Neoplasms | Details |
| JNJ-70218902 | JNJ-70218902 | Phase 1 Clinical | Janssen Global Services Llc | Neoplasms | Details |
| RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
| JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Janssen Global Services Llc, Genmab A/S | Leukemia, Myeloid, Acute | Details |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| AMG-509 | AMG-509 | Phase 1 Clinical | Amgen Inc, Xencor Inc | Prostatic Neoplasms | Details |
| hEGFRvIII-CD3 Bi-scFv | Phase 1 Clinical | Duke University | Glioblastoma; Glioma | Details | |
| Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Multiple Myeloma | Details |
| ASP-2138 | ASP-2138 | Phase 1 Clinical | Astellas Pharma Global Development Inc, Xencor Inc | Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms | Details |
| α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms | Details |
| TNB-486 | TNB-486 | Phase 1 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
| Anti-CD3/humanized 3F8 bispecific antibody-activated T lymphocytes (University of Virginia) | Phase 2 Clinical | University Of Virginia | Neuroblastoma | Details | |
| BI-765049 | BI-765049; OBT-624 | Phase 1 Clinical | Boehringer Ingelheim Gmbh | Head and Neck Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
| Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Breast Neoplasms; Prostatic Neoplasms | Details | |
| Runimotamab | BTRC-4017A; RG-6194 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
| Vixtimotamab | T-564; AMV-564 | Phase 1 Clinical | Amphivena Therapeutics Inc | Solid tumours; Myelodysplastic Syndromes | Details |
| Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia) | Phase 1 Clinical | University Of Virginia | Multiple Myeloma | Details | |
| GR-1803 | GR-1803 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd | Multiple Myeloma | Details |
| K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
| GNC-035 quadr-specific antibody（baili） | GNC-035 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| Tidutamab | XmAb-18087 | Phase 2 Clinical | Xencor Inc | Carcinoma, Merkel Cell; Small Cell Lung Carcinoma | Details |
| EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Solid tumours | Details |
| OBT620 | OBT620 | Phase 1 Clinical | Boehringer Ingelheim Gmbh, Oxford Biotherapeutics Ltd | Small Cell Lung Carcinoma | Details |
| RO-7444973 | RO-7444973 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
| TAK-186 | EGFR x CD3 COBRA; MVC-101; TAK-186 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Anti-CD3 monoclonal antibody (Jinan Tiankang Biological Products) | Phase 2 Clinical | Jinan Tiankang Biological Products Co Ltd | Anemia, Aplastic | Details | |
| EX-103 | EX-103; EX103 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| CX-904 | CX-904 | Phase 1 Clinical | Amgen Inc, Cytomx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| CN-201 | CN-201 | Phase 2 Clinical | Tongrun Biomedicine (Shanghai) Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Cibisatamab | CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| JNJ-75348780 | Phase 1 Clinical | Janssen Research & Development Llc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
| Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
| ARB-202 | ARB-202 | Phase 1 Clinical | Arbele Corp | Liver Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Gastrointestinal Neoplasms | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis | Details |
| RG-6232 | RG-6232 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Melanoma | Details |
| CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| PF-07260437(Pfizer) | PF-07260437 | Phase 1 Clinical | Pfizer Inc | Ovarian Neoplasms; Breast Neoplasms; Endometrial Neoplasms | Details |
| BNT-142 | BNT-142 | Phase 2 Clinical | Biontech Se | Solid tumours | Details |
| MGD-014 | MGD-014 | Phase 1 Clinical | Macrogenics Inc | HIV Infections | Details |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| Alnuctamab | CC-93269; EM-901 | Phase 1 Clinical | Multiple Myeloma | Details | |
| TQB-2825 | TQB-2825 | Phase 1 Clinical | Wuxi Biologics Co Ltd | Hematologic Neoplasms; Neoplasms | Details |
| SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
| ERY-974 | ERY-974 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
| CBA-1535 | CBA-1535 | Phase 1 Clinical | Chiome Bioscience Inc | Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung | Details |
| TAK-280 | MVC-280; TAK-280 | Phase 2 Clinical | Maverick Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| RO-7428731 | RO-7428731 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Glioblastoma | Details |
| F-182112 | F-182112; F182112 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
| QLS-31904 | QLS31904; QLS-31904 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Solid tumours | Details |
| GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Membrane bound ligand T-SIGn virus | NG-348 | Phase 1 Clinical | Neoplasms | Details | |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Leukemia, Myeloid, Acute | Details |
| Acapatamab | AMG-160 | Phase 2 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Multiple Myeloma | Details | |
| CC-312 | CC-312 | Phase 1 Clinical | Details | ||
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
| SMET-12 | SMET-12 | Phase 1 Clinical | Zhejiang Shimai Pharmaceutical Co Ltd | Solid tumours | Details |
| REGN-5459 | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| CM-336(Connaught Biomedical Technology) | CM-336 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Multiple Myeloma | Details |
| JS-203 | JS-203 | Phase 1 Clinical | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
| RO-7293583 | RO-7293583 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Skin Melanoma; Uveal melanoma; Melanoma | Details |
| CM-350 | CM-350 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Solid tumours | Details |
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) | Phase 2 Clinical | Barbara Ann Karmanos Cancer Institute, University Of Virginia | Glioblastoma; Pancreatic Neoplasms | Details | |
| APVO436 | APVO-436 | Phase 1 Clinical | Aptevo | Myeloproliferative Disorders; Leukemia, Myeloid, Acute | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
| GB-261 | GB-261 | Phase 2 Clinical | Genor Biopharma Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Leukemia, Promyelocytic, Acute; Hematologic Neoplasms | Details |
| JNJ-78278343 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details | |
| JNJ-67571244 | JNJ-67571244; JNJ-67371244; JNJ-1244 | Phase 1 Clinical | Johnson & Johnson | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics) | Phase 1 Clinical | Y-Mabs Therapeutics Inc | Leukemia, Myeloid, Acute | Details | |
| IMC-F106C | IMC-F106C | Phase 2 Clinical | Immunocore Ltd | Solid tumours | Details |
| BI-764532 | BI-764532 | Phase 1 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Small Cell Lung Carcinoma; Neoplasms | Details |
| JANX-007 | JANX-007; PSMA-TRACTr | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| Odronextamab | REGN-1979 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| REGN-4336 | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| HPN-424 | HPN-424 | Phase 2 Clinical | Harpoon Therapeutics | Prostatic Neoplasms | Details |
| JNJ-78306358 | JNJ-78306358; JNJ-6358 | Phase 1 Clinical | Janssen Research & Development Llc | Neoplasms | Details |
| 1-A-46 | BR-110; 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| CC-1 | CC-1 | Phase 2 Clinical | The University Of Tubingen, German Cancer Research Center (Dkfz) | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell | Details |
| M-701 | M-701 | Phase 2 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Hydrothorax; Neoplasms; Ascites; Pleural Effusion, Malignant; Carcinoma, Non-Small-Cell Lung | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| CLN-978 | CLN-978 | Phase 1 Clinical | Adimab LLC | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| PIT-565 | PIT-565 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
| YK-012 | YK012 | Phase 1 Clinical | Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd | Lymphoma, B-Cell | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, T-Cell | Details |
| TNB-585 | AMG-340; TNB-585 | Phase 1 Clinical | Teneobio Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| Cevostamab | RG-6160; BFCR-4350A; RO-7187797 | Phase 2 Clinical | Genentech Inc | Multiple Myeloma | Details |
| RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
| AMG-794 | AMG-794 | Phase 1 Clinical | Amgen Inc | Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung | Details |
| Tepoditamab | MCLA-117 | Phase 1 Clinical | Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc | Leukemia, Myeloid, Acute | Details |
| Ubamatamab | REGN-4018 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| NVG-111 | NVG-111 | Phase 2 Clinical | NovalGen Ltd | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| Linvoseltamab | REGN-5458 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) | CM-355 | Phase 2 Clinical | Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Hematoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
| GEM3-PSCA | GEM3-PSCA | Phase 1 Clinical | Gemoab Monoconals, Gcp Service International | Kidney Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| AMG-199 | AMG-199 | Phase 1 Clinical | Amgen Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms | Details |
| IMC-C103C | IMC-C103C; RG-6290 | Phase 2 Clinical | Immunocore Ltd | Solid tumours | Details |
| AMG-562 | AMG-562 | Phase 1 Clinical | Amgen Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular | Details |
| Foralumab | NI-0401/α-CD3; TZLS-401; NI-0401 | Phase 2 Clinical | Novimmune Sa, Bristol-Myers Squibb Company | Respiratory Tract Infections; Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Crohn Disease | Details |
| Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 2 Clinical | Macrogenics Inc | Leukemia; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia, Hairy Cell; Hodgkin Disease; Mastocytosis, Systemic; Blastic Plasmacytoid Dendritic Cell Neoplasm; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
| BCMA TriTAC | HPN-217 | Phase 1 Clinical | Harpoon Therapeutics, Abbvie Inc | Multiple Myeloma | Details |
| Catumaxomab | LP000 | Phase 3 Clinical | Trion Research, Neovii Biotech Gmbh | Ovarian Neoplasms; Stomach Neoplasms; Carcinoma; Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Ascites; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| MBS-303 | MBS-303 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Lymphoma, B-Cell | Details |
| EMB-07 | EMB-07 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Neoplasms; Adenocarcinoma of Lung; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Uterine Neoplasms | Details |
| LBL-033 | LBL-033 | Phase 1 Clinical | Nanjing Leads Biolabs Co Ltd | Neoplasms | Details |
| NG-641 | NG-641; NG-aFAP; EnAd-FAP-Tac; EnAd-FAP-BiTE | Phase 1 Clinical | University Of Oxford, Akamis Bio Ltd | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.
A-Z
